Mr. Peter Shippen reports

BRITANNIA ANNOUNCES NORMAL COURSE ISSUER BID

Further to the news release dated May 21, 2026, Britannia Life Sciences Inc. will commence a normal course issuer bid to purchase for cancellation, from time to time over a 12-month period starting Aug. 10, 2026, common shares of the company in an aggregate amount of up to 8,112,717 common shares, representing 5 per cent of Britannia's issued and outstanding common shares. The NCIB will end on Aug. 9, 2027, unless the maximum number of common shares is purchased before then or the company provides earlier notice of termination.

The board and management of the company believe that the market price of the common shares may not fully reflect the value of its business and prospects, and, as such, believes that purchasing the common shares for cancellation is an appropriate strategy for increasing long-term shareholder value and represents an appropriate use of the company's financial resources.

The purchase and payment for the common shares will be made by the company through the facilities of the Canadian Securities Exchange or alternative trading systems. The price paid for the common shares will be, subject to the applicable laws, the prevailing market price of such common shares on the CSE at the time of such purchase. Any common shares purchased by the company will be cancelled.

About Britannia Life Sciences Inc.

Britannia is a Canadian public company operating as a diversified service and investment platform. The company functions as a public market venture builder, originating, founding, capitalizing and operationally supporting new businesses across selected sectors, with the objective of creating long-term shareholder value through cornerstone equity positions and defined liquidity outcomes.

We seek Safe Harbor.